<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480672</url>
  </required_header>
  <id_info>
    <org_study_id>ADRISK</org_study_id>
    <nct_id>NCT03480672</nct_id>
  </id_info>
  <brief_title>Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>Postoperative Adjuvant Radiochemotherapy (aRCH) With Cisplatin (C) Versus aRCH With C and Pembrolizumab (P) in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC); Multicenter Randomized Phase II Study Within the German Interdisciplinary Study Group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial evaluates the addition of pembrolizumab to standard postoperative adjuvant
      radiochemotherapy in the treatment of patients with locally advanced intermediate and high
      risk head and neck squamous cell carcinoma (HNSCC).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>24 months</time_frame>
    <description>time from randomization to the first event (i.e. locoregional or distant recurrence, initiation of a new anti-cancer treatment death from any cause)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>time from randomization to death from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>HNSCC</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + aRCH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of pembrolizumab, i.v., in 3-week cycle (q3w) 200 mg, in combination with standard treatment (adjuvant radio-chemotherapy aRCH)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aRCH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adjuvant radio-chemotherapy (aRCH)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]</intervention_name>
    <description>intravenous application, 12 months, in 3-week cycle (q3w) 200 mg</description>
    <arm_group_label>Pembrolizumab + aRCH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>adjuvant radiochemotherapy</intervention_name>
    <description>adjuvant radiochemotherapy with cisplatin</description>
    <arm_group_label>Pembrolizumab + aRCH</arm_group_label>
    <arm_group_label>aRCH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Macroscopically complete resection of newly diagnosed advanced squamous-cell carcinoma
             arising in the oral cavity, oropharynx, larynx, or hypopharynx

          2. Advanced stage III, IVA/B HNSCC according to the TNM classification version 7th
             edition

          3. Eastern Cooperative Oncology Group performance status of 0 to 1

          4. Had either intermediate or high-risk characteristics, i.e. any or all of the
             following:

               -  histologic evidence of invasion of two or more regional lymph nodes

               -  extracapsular extension of nodal disease,

               -  microscopically involved mucosal margins of resection (R1) or margins of
                  resection &lt; 5mm (R0)

          5. Had pathological histologic assessment of p16 (only oropharyngeal carcinoma)

          6. Be 18 years

          7. Written informed consent

          8. Demonstrate adequate organ function

          9. Female subject of childbearing potential should have a negative pregnancy test within
             3 days prior to receiving the first dose of study medication.

         10. Female subjects of childbearing potential must be willing to use an adequate method of
             contraception, for the course of the study through 120 days after the last dose of
             study medication.

         11. Reproductive male subjects must agree to use an adequate method of contraception,
             starting with the first dose of study therapy through 120 days after the last dose of
             study therapy

        Exclusion Criteria:

          1. Is currently participating and receiving study therapy or has participated in a study
             with an investigational agent and received study therapy or used an investigational
             device within one month before enrolment into this trial.

          2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days before enrolment into this
             trial.

          3. Has a known history of active TB

          4. Hypersensitivity to Pembrolizumab or comparable medicinal products or any of its
             excipients.

          5. Has had a prior anti-cancer monoclonal antibody therapy within one month before
             enrolment into this trial or who has not recovered from adverse events due to agents
             administered more than one month earlier.

          6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within one month before enrolment into this trial or who has not recovered from
             adverse events due to a previously administered agent.

          7. Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer.

          8. Has active autoimmune disease that has required systemic treatment in the past 2 years
             prior to enrolment. Replacement therapy is not considered a form of systemic
             treatment.

          9. Has evidence of interstitial lung disease or history of (non-infectious) pneumonitis
             that required steroids within the last 6 months before enrolment into this trial, or
             current pneumonitis.

         10. Has an active infection requiring systemic therapy.

         11. Suspected lack of compliance

         12. Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the baseline visit through 120 days
             after the last dose of trial treatment.

         13. Known HIV, HBV or HCV infection

         14. Has received a live vaccine within one month of enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Dietz, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Dietz, Prof. Dr.</last_name>
    <phone>0049 34197</phone>
    <phone_ext>21700</phone_ext>
    <email>andreas.dietz@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anett Schmiedeknecht, Dr.</last_name>
    <phone>0049 34197</phone>
    <phone_ext>16256</phone_ext>
    <email>anett.schmiedeknecht@zks.uni-leipzig.de</email>
  </overall_contact_backup>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Andreas Dietz</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

